Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant status, or immunosenescence. Given its rarity, there is no specific standard treatment for PBL. H...

Full description

Bibliographic Details
Main Authors: Lili Cheng, Qi Song, Mengke Liu, Yan Wang, Hongmei Yi, Ying Qian, Pengpeng Xu, Shu Cheng, Chaofu Wang, Li Wang, Weili Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitor
tislelizumab
lenalidomide
Epstein-Barr virus
plasmablastic lymphoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.702593/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.702593/full

Similar Items